Who are Tramadol 5%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tramadol IV (Tradonal® IV), placebo and tramadol, Tramadol HCl, Tramadol PR oral.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tramadol-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tramadol 5% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tramadol 5% (Tramadol 5%) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic with monoamine reuptake inhibition. Area: Pain Management.

phase 3 Opioid analgesic with monoamine reuptake inhibition Mu opioid receptor; norepinephrine and serotonin transporters Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Tramadol 5% (Tramadol 5%) — Al-Azhar University. Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and inhibits the reuptake of norepinephrine and serotonin to produce pain relief.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tramadol 5% TARGET	Tramadol 5%	Al-Azhar University	phase 3	Opioid analgesic with monoamine reuptake inhibition	Mu opioid receptor; norepinephrine and serotonin transporters
Tramadol IV (Tradonal® IV)	Tramadol IV (Tradonal® IV)	University Hospital, Ghent	marketed	Opioid analgesic with monoamine reuptake inhibition	Mu opioid receptor; norepinephrine transporter; serotonin transporter
placebo and tramadol	placebo and tramadol	University of Southern Denmark	marketed	Opioid analgesic with monoamine reuptake inhibition	Mu-opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol HCl	Tramadol HCl	Labopharm Inc.	marketed	Synthetic opioid analgesic with monoamine reuptake inhibition	Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol PR oral	Tramadol PR oral	Pfizer	phase 3	Opioid analgesic with monoamine reuptake inhibition	Mu opioid receptor; norepinephrine transporter; serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic with monoamine reuptake inhibition class)

Al-Azhar University · 1 drug in this class
Pfizer · 1 drug in this class
University Hospital, Ghent · 1 drug in this class
University of Southern Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tramadol 5% — Competitive Intelligence Brief. https://druglandscape.com/ci/tramadol-5. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing